It's How Medicine Should Be®


French German Italian Portuguese Russian

Study for Patients with Newly Diagnosed Acute Myeloid Leukemia

Clinical Trial Title: 
Midostaurin in adult patients with FLT3 mutated AML.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Melissa L. Larson, MD
Clinical Trial Protocol Description: 

To provide midostaurin treatment during induction, consolidation and continuation for adult patients with newly diagnosed FLT3 mutated AML and to collect additional data on treatment safety.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are 18 years of age or older. Elderly patients must be fit to receive intensive induction and consolidation chemotherapy.
  • Have newly diagnosed, morphologically documented primary AML or AML secondary to MDS based on WHO 2008 classification.
  • Have documented FLT3 mutation (ITD or TKD).

You will be excluded from the study if any of the following criteria apply to you:

  • Have had prior therapy for AML.
  • Have LVEF <45% or symptomatic congestive heart failure.
  • Have any pulmonary infiltrates.
  • Have QTc>500 msec.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-1346
Contact Name: 
Kimberly Koetter, BS, RN, OCN, CCRC